Tanespimycin Production Cost Reports - 2018/19

Capital Investment & Operating Cost of Tanespimycin Plants

Tanespimycin is an inhibitor of a heat shock protein that plays a central role in promoting the functionality and stability of a group of proteins associated with cancer. Tanespimycin is a derivative of geldanamycin, an antibiotic that is being studied in the treatment of cancer and patients with certain types of leukemia or tumors.

Intratec offers professional, easy-to-understand reports examining Tanespimycin production. Each study describes an industrial plant, including main process units and site infrastructure, and presents an independent analysis of capital and operating costs. All reports are based on the most recent economic data available (2018/19).

Use our Reports as

Feasibility Studies

Techno-economic Evaluations

Investment Analyses

Multi-regional Cost Analyses

Trusted By

BASF
Monsanto
Linde

Additional Info

  • Product Alias: production-cost-report
  • Referer Theme: Tanespimycin

See Full Samples of Production Cost Reports

Register now for a Free Trial and access full samples of Intratec Production Cost Reports, sharing the same structure and development methodology of the production cost reports above!

Free Trial also includes:

  • Pricing Data of +110 Chemicals Around the World
  • Cost Data of Utilities, in Several Countries
  • Reports Detailing Processes and Costs of Production
  • Tools for Assessing Costs of Plants Worldwide